AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03153696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit Intervention
Description: The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
Study NCT03153696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cellie Coping Kit Intervention
Description: The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
Study NCT03495466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local only anesthesia vs Local with sedation anesthesia
Description: The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
Study NCT02066766 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study NCT02371824 — intervention group
Intervention type: OTHER
Intervention: MRI sequence
Description: One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
Study NCT04340635 — intervention group
Intervention type: OTHER
Description: Without intervention
Study NCT00955214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté paclitaxel-eluting coronary stent system
Description: diameter is 2.5mm
Study NCT02326038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: single oral administration of 20 mg tablet
Study NCT01859234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-bevacizumab
Description: 89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT500
Description: FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immune Checkpoint Inhibitor
Study NCT02374892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAPTER III Study Intervention
Description: This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
Study NCT00486629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and dietary education
Description: Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune Checkpoint Inhibitor
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Immune Checkpoint Inhibitor
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study NCT04535804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin/placebo
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT03841110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study NCT01677689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomivir®
Description: Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Study NCT01677689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Study NCT00649844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
Study NCT00649844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
Study NCT03980015 — intervention group
Intervention type: OTHER
Intervention: antibiotic treatment
Description: Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
Study NCT01601535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Description: Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
Study NCT01601535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously during each course on study day 1 through day 5.
Study NCT01601535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally during each course on study day 1 through day 5.
Study NCT04535804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin/placebo
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Study NCT03821753 — intervention group
Intervention type: OTHER
Intervention: Case
Description: * OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests
Study NCT03821753 — intervention group
Intervention type: OTHER
Intervention: Control
Description: * OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks of placebo PO daily
Study NCT02006953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus feeding schedule following gastrostomy tube placement
Study NCT02006953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous chimney feeds following gastrostomy tube placement
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 weeks of placebo PO daily
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 weeks of placebo PO daily
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
Study NCT02495324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan medoxomil
Description: 10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
Study NCT03849313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases
Study NCT03084796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Dose Response: Test one of four different doses of CHF 5259
Study NCT03084796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study NCT03084796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide 18 µg Inhalation Capsule
Description: Active Control
Study NCT04043117 — intervention group
Intervention type: OTHER
Intervention: Body Image evaluation
Description: Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves.
Study NCT04043117 — intervention group
Intervention type: OTHER
Intervention: Self esteem evaluation
Description: Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false.
Study NCT03651037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrivors+BH
Description: Digital health platform for breast cancer patients that measures adherence and engagement.
Study NCT02530346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Mechanical Bowel Preparation
Description: no enemas or oral laxatives will be given in this group
Study NCT02530346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
Study NCT03243617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications
Study NCT03243617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications
Study NCT03243617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AO+Mist
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications
Study NCT03243617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AO+Mist
Description: Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications
Study NCT02068924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow freezing versus vitrification
Study NCT02068924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Slow freezing versus vitrification
Study NCT03247257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients will be put under general anesthesia for cholecystectomy
Study NCT03247257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Anesthesia
Description: Patients will receive Epidural Anesthesia for cholecystectomy
Study NCT02485691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel XRP6258
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT02485691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Pharmaceutical form: capsule Route of administration: oral
Study NCT02485691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02485691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02864589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered habit reversal training
Description: The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
Study NCT02864589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure and response prevention
Description: The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
Study NCT02376634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: Patients will be taught self-hypnosis.
Study NCT02997501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T790M+ Testing
Description: The patient will need to have T790M+ testing
Study NCT02997501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline Visit Blood & Urine Testing
Description: Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Study NCT02997501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline ECG
Description: ECG to ensure absence of any cardiac abnormality
Study NCT02997501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Slit-Lamp Testing
Description: Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
Study NCT02997501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 Dosing
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Study NCT02997501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma AZD9291 testing
Description: The patient will need to have plasma AZD9291 testing before treatment
Study NCT01979367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodyne
Description: Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
Study NCT02567981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 21 micronutrient-fortified supplement
Description: 21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.